文献速递前列腺癌

罕见组织学亚型前列腺癌:癌症特异性死亡与其他原因死亡

Rare histological prostate cancer subtypes: Cancer-specific and other-cause mortality.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-07-10

基于监测、流行病学和最终结果数据库(2004—2020年)827549例患者,采用平滑累积发生率图和竞争风险回归分析罕见组织学亚型前列腺癌的癌症特异性死亡(CSM)与其他原因死亡(OCM)。神经内分泌癌各分期及局部进展期导管癌的CSM率高于腺泡腺癌,黏液性癌和印戒细胞癌的CSM率与腺泡腺癌无差异。

要点

  • 神经内分泌癌各分期CSM率均高于腺泡腺癌,局部进展期HR 9.66。
  • 局部进展期导管癌CSM率高于腺泡腺癌,HR 2.26。
  • 黏液性癌和印戒细胞癌的CSM率与腺泡腺癌无显著差异。

核心结论

  • 与腺泡腺癌相比,神经内分泌癌各分期患者及局部进展期导管癌患者的CSM率更高;黏液性腺癌和印戒细胞腺癌的CSM率与腺泡腺癌无差异。

研究设计与样本

  • 基于监测、流行病学和最终结果数据库(2004—2020年)的队列分析,共纳入827549例患者,采用平滑累积发生率图和竞争风险回归模型。

主要发现

  • 827549例中,导管癌1510例(0.18%),神经内分泌癌952例(0.12%),黏液性癌462例(0.06%),印戒细胞癌95例(0.01%)。
  • 局限期:腺泡腺癌5年CSM 2% vs OCM 10%,黏液性癌3% vs 8%,神经内分泌癌55% vs 19%。
  • 局部进展期:腺泡腺癌5年CSM 5% vs OCM 6%,导管癌14% vs 16%,神经内分泌癌71% vs 15%。
  • 转移期:印戒细胞癌5年CSM 49% vs OCM 15%,黏液性癌56% vs 16%,导管癌63% vs 9%,神经内分泌癌85% vs 12%。
  • 多因素竞争风险回归:局限期神经内分泌癌HR 3.09,局部进展期神经内分泌癌HR 9.66,局部进展期导管癌HR 2.26,转移期神经内分泌癌HR 3.57(均p < 0.001),CSM率均高于腺泡腺癌。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To assess cancer-specific mortality (CSM) and other-cause mortality (OCM) rates in patients with rare histological prostate cancer subtypes. METHODS: Using the Surveillance, Epidemiology, and End Results database (2004-2020), we applied smoothed cumulative incidence plots and competing risks regression (CRR) models. RESULTS: Of 827,549 patients, 1510 (0.18%) harbored ductal, 952 (0.12%) neuroendocrine, 462 (0.06%) mucinous, and 95 (0.01%) signet ring cell carcinoma. In the localized stage, five-year CSM vs. OCM rates ranged from 2 vs. 10% in acinar and 3 vs. 8% in mucinous, to 55 vs. 19% in neuroendocrine carcinoma patients. In the locally advanced stage, five-year CSM vs. OCM rates ranged from 5 vs. 6% in acinar, to 14 vs. 16% in ductal, and to 71 vs. 15% in neuroendocrine carcinoma patients. In the metastatic stage, five-year CSM vs. OCM rates ranged from 49 vs. 15% in signet ring cell and 56 vs. 16% in mucinous, to 63 vs. 9% in ductal and 85 vs. 12% in neuroendocrine carcinoma. In multivariable CRR, localized neuroendocrine (HR 3.09), locally advanced neuroendocrine (HR 9.66), locally advanced ductal (HR 2.26), and finally metastatic neuroendocrine carcinoma patients (HR 3.57; all p < 0.001) exhibited higher CSM rates relative to acinar adenocarcinoma patients. CONCLUSIONS: Compared to acinar adenocarcinoma, patients with neuroendocrine carcinoma of all stages and locally advanced ductal carcinoma exhibit higher CSM rates. Conversely, CSM rates of mucinous and signet ring cell adenocarcinoma do not differ from those of acinar adenocarcinoma.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Siech C, de Angelis M, Jannello LMI, et al. Rare histological prostate cancer subtypes: Cancer-specific and other-cause mortality. Prostate Cancer Prostatic Dis. 2024. PMID: 38987307. doi:10.1038/s41391-024-00866-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。